Sanjivani Paranteral (SANJIVIN) | Financial Analysis & Statements
Sanjivani Paranteral Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
178.9M
Gross Profit
67.8M
37.88%
Operating Income
24.8M
13.88%
Net Income
17.3M
9.67%
EPS (Diluted)
₹1.41
Balance Sheet Metrics
Total Assets
782.0M
Total Liabilities
383.3M
Shareholders Equity
398.7M
Debt to Equity
0.96
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Sanjivani Paranteral Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 695.6M | 536.9M | 352.4M | 303.8M | 247.1M |
| Cost of Goods Sold | 444.0M | 328.0M | 218.2M | 152.4M | 166.4M |
| Gross Profit | 251.6M | 208.9M | 134.2M | 151.4M | 80.7M |
| Gross Margin % | 36.2% | 38.9% | 38.1% | 49.8% | 32.7% |
| Operating Expenses | |||||
| Research & Development | 5.7M | 646.2K | 0 | - | - |
| Selling, General & Administrative | 77.1M | 85.7M | 45.9M | 58.8M | 23.9M |
| Other Operating Expenses | 1.4M | -610.7K | -2.5M | 8.4M | 220.8K |
| Total Operating Expenses | 84.2M | 85.8M | 43.4M | 67.2M | 24.1M |
| Operating Income | 97.3M | 74.8M | 48.0M | 44.8M | 25.1M |
| Operating Margin % | 14.0% | 13.9% | 13.6% | 14.8% | 10.1% |
| Non-Operating Items | |||||
| Interest Income | 3.3M | 324.2K | 74.0K | 41.5K | 166.3K |
| Interest Expense | 4.1M | 1.2M | 2.3M | 832.6K | 78.2K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 103.5M | 75.7M | 49.4M | 48.8M | 14.1M |
| Income Tax | 22.6M | 14.1M | 4.3M | 321.5K | -71.5K |
| Effective Tax Rate % | 21.8% | 18.6% | 8.8% | 0.7% | -0.5% |
| Net Income | 80.9M | 61.7M | 45.1M | 48.5M | 14.2M |
| Net Margin % | 11.6% | 11.5% | 12.8% | 16.0% | 5.7% |
| Key Metrics | |||||
| EBITDA | 113.9M | 87.8M | 60.7M | 54.7M | 35.1M |
| EPS (Basic) | ₹6.89 | ₹5.28 | ₹4.51 | ₹4.85 | ₹1.67 |
| EPS (Diluted) | ₹6.66 | ₹5.28 | ₹4.51 | ₹4.85 | ₹1.67 |
| Basic Shares Outstanding | 11752990 | 11684300 | 9998300 | 9998300 | 8498300 |
| Diluted Shares Outstanding | 11752990 | 11684300 | 9998300 | 9998300 | 8498300 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Sanjivani Paranteral Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 14.9M | 5.4M | 3.0M | 3.4M | 1.7M |
| Short-term Investments | 9.3M | 90.2M | 3.4M | - | - |
| Accounts Receivable | 166.8M | 47.0M | 19.9M | 49.2M | 66.3M |
| Inventory | 105.1M | 97.3M | 53.5M | 17.5M | 9.1M |
| Other Current Assets | - | - | - | 4.9M | 11.7M |
| Total Current Assets | 341.8M | 286.4M | 82.7M | 77.3M | 91.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 386.4K | 386.4K | 386.4K | 386.4K | 361.3K |
| Goodwill | 1.6M | 0 | 0 | 0 | 0 |
| Intangible Assets | 782.0K | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | 17.0K | - | - |
| Total Non-Current Assets | 440.2M | 147.7M | 127.4M | 105.7M | 100.9M |
| Total Assets | 782.0M | 434.1M | 210.1M | 183.0M | 192.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 152.5M | 57.4M | 137.2M | 114.4M | 105.9M |
| Short-term Debt | 28.5M | 0 | 17.3M | 32.4M | 407.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 121.5M | 70.2M | 64.2M | 97.4M | 96.8M |
| Total Current Liabilities | 317.9M | 137.8M | 226.5M | 218.9M | 576.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 52.9M | 9.7M | 7.6M | 27.5M | 53.0M |
| Deferred Tax Liabilities | 7.7M | 3.5M | 3.1M | 9.2M | 8.8M |
| Other Non-Current Liabilities | -2 | -1 | -1 | 1 | -1 |
| Total Non-Current Liabilities | 65.3M | 17.3M | 14.3M | 39.9M | 65.4M |
| Total Liabilities | 383.3M | 155.1M | 240.8M | 258.8M | 641.7M |
| Equity | |||||
| Common Stock | 118.8M | 116.8M | 100.0M | 100.0M | 85.0M |
| Retained Earnings | -427.9M | -508.9M | -570.5M | -615.6M | -664.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 398.7M | 279.0M | -30.7M | -75.8M | -448.9M |
| Key Metrics | |||||
| Total Debt | 81.4M | 9.7M | 24.9M | 59.9M | 460.6M |
| Working Capital | 23.9M | 148.6M | -143.9M | -141.7M | -484.4M |
Balance Sheet Composition
Sanjivani Paranteral Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 103.5M | 75.7M | 49.4M | 48.8M | 14.1M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -69.4M | -99.9M | -32.2M | 33.9M | -19.8M |
| Operating Cash Flow | 35.9M | -23.6M | 19.0M | 83.5M | -5.7M |
| Investing Activities | |||||
| Capital Expenditures | -303.5M | -33.0M | -10.5M | -6.8M | -4.3M |
| Acquisitions | 0 | - | - | - | - |
| Investment Purchases | - | -90.2M | - | - | - |
| Investment Sales | 81.0M | 500.0K | - | - | - |
| Investing Cash Flow | -123.6M | -122.8M | -10.5M | -6.8M | -4.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 71.7M | - | - | - | - |
| Debt Repayment | 0 | - | - | -91.0M | -28.5M |
| Financing Cash Flow | 109.7M | 248.0M | 0 | -76.0M | -2.5M |
| Free Cash Flow | -179.5M | -140.1M | 35.9M | 78.4M | 1.5M |
| Net Change in Cash | 22.1M | 101.7M | 8.5M | 689.5K | -12.6M |
Cash Flow Trend
Sanjivani Paranteral Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.38
Price to Book
4.60
Price to Sales
2.79
PEG Ratio
0.70
Profitability Ratios
Profit Margin
11.23%
Operating Margin
16.37%
Return on Equity
20.31%
Return on Assets
10.35%
Financial Health
Current Ratio
1.38
Debt to Equity
19.66
Beta
-0.53
Per Share Data
EPS (TTM)
₹6.60
Book Value per Share
₹36.39
Revenue per Share
₹60.76
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SANJIVIN | 2.1B | 25.38 | 4.60 | 20.31% | 11.23% | 19.66 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





